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Due to their capacity to inhibit hexosaminidases, 2-acetamido-1,2-dideoxy-iminosugars have been
widely studied as potential therapeutic agents for various diseases. An efﬁcient stereoselective synthesis
of 2-acetamido-1,2-dideoxyallonojirimycin (DAJNAc), the most potent inhibitor of human placenta b-N-
acetylglucosaminidase (b-hexosaminidase) among the epimeric series, is here described. This novel
procedure can be easily scaled up, providing enough material for structural modiﬁcations and further
biological tests. Thus, two series of sp2-iminosugar conjugates derived from DAJNAc have been prepared,
namely monocyclic DAJNAc-thioureas and bicyclic 2-iminothiazolidines, and their glycosidase inhibitory
activity evaluated. The data evidence the utmost importance of developing diversity-oriented synthetic
strategies allowing optimization of electrostatic and hydrophobic interactions to achieve high inhibitory
potencies and selectivities among isoenzymes. Notably, strong differences in the inhibition potency of
the compounds towards b-hexosaminidase from human placenta (mature) or cultured ﬁbroblasts (pre-
cursor form) were encountered. The ensemble of data suggests that the ratio between them, and not the
inhibition potency towards the placenta enzyme, is a good indication of the chaperoning potential of
TaySachs disease-associated mutant hexosaminidase.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glycosidases comprise a broad class of enzymes that participate
in metabolic processes which are essential for cell life and cell
communication, including the catabolism of polysaccharides andBiomedicine (IRB Barcelona),
aldiri Reixac 10, 08028 Bar-
igaki), mellet@us.es (C. Ortiz
Masson SAS. This is an open accessglycoconjugates and the trimming of the oligosaccharides present
in glycoproteins and glycolipids. Consequently, compounds with
selective glycosidase inhibitory or effector activity have strong
therapeutic potential in the treatment of pathologies resulting from
glycosidase deregulation, including diabetes, cancer, viral and
bacterial infection, and lysosomal storage diseases, among others
[1e5]. Iminosugars, structural analogs of monosaccharides (glyco-
mimetics) in which the ring oxygen has been replaced by nitrogen,
comprise by far the most studied family of compounds towards this
end [6e8]. Their ability to mimic the glycosyloxacarbenium cati-
onda key intermediate in enzymatic glycoside hydrolysis [9]din
their protonated state translates into high binding afﬁnities to-
wards complementary glycosidases. The broad range of potentialarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Scheme 2. Retrosynthetic analysis.
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vation for synthetic chemists. In this regard, a plethora of analogs
has been reported [10e22], some of which are currently on the
market, such as N-butyl-1-deoxynojirimycin (Zavesca®) for the
treatment of type 1 Gaucher disease and miglitol (Glyset®) for the
treatment of type II diabetes mellitus.
From the structural point of view, iminosugars share a poly-
hydroxylated iminoheterocyclic skeleton that differs in the size of
the ring, the stereochemical pattern, and the substitution proﬁle
[23]. While efﬁcient methods for the introduction of a variety of
substituents at the region of the ring nitrogen [24e26] or the
pseudoanomeric carbon [27e36] have been reported, replacing
hydroxyl groups at non-pseudoanomeric positions by other func-
tionalities such as amide groups, remains a challenge. This might be
critical in the design of modulators of particular glycosidase targets.
Thus, the dysfunction of hexosaminidases, the glycosidases
involved in the hydrolysis of 2-acetamido-2-deoxyglycosides, has
been associated with diseases such as osteoarthritis [37,38], Alz-
heimer [39], O-GlcNAcase inhibition [40] and the lysosomal storage
diseases Tay-Sachs [41], Sandhoff [42] and Schindler-Kazaki [43].
Not surprisingly, acetamido-iminosugars inhibit these enzymes
and have become interesting candidates in the development of
pharmacological chaperones for the treatment of some of these
conditions [9].
In 1986, Fleet et al. [44,45] described the ﬁrst synthesis of 2-
acetamido-1,2-dideoxy-D-nojirimycin (DNJNAc; 2), a mimetic of
N-acetylglucosamine (GlcNAc; 1) that is a potent and highly speciﬁc
inhibitor of b-N-acetylglucosaminidases (b-GlcNAcases) (Scheme
1). Further studies have proved that modiﬁcations on the amide
functionality do not improve the inhibitory capacity of this com-
pound [46]. The galacto congener DGJNAc (3) [47] and derivatives
[48] fall in the same inhibition range for b-GlcNAcases and are also
potent inhibitors of a-N-acetylgalactosaminidase (a-GalNAcase)
[43] while the manno congener DMJNAc (4) shows no hexosa-
minidase inhibition [49]. A range of other glycomimetic-type in-
hibitors has been reported, but all of them suffer from lack of
selectivity among b-GlcNAcase isoforms and poor drug-like phys-
icochemical properties [50]. The development of novel and speciﬁc
inhibitors susceptible of systematic chemical modiﬁcation for
structureeactivity relationship studies is thus a priority to exploit
the potential of function-speciﬁc b-GlcNAcase activity modulation
in terms of drug design and biological research. Conjugation of
acetamido-iminosugar with organic fragments susceptible of
imparting amphiphilicity and providing additional interactionsScheme 1. Structures of N-acetylglucosamine (1) awith the aglycone site of the enzyme has shown high promise at
this respect [51]. Yet, the approach is handicapped by the fact that
most synthetic approaches to 2-acetamido iminosugars are based
on the chiral pool and often involve long and tedious trans-
formations from carbohydrate precursors [12,52].
We have recently published the ﬁrst asymmetric synthesis of
the allo-conﬁgured acetamido-iminosugar representative, namely
2-acetamido-1,2-dideoxyallonojirimycin (DAJNAc; 5), in only six
steps from the bicyclic precursor 7 (Scheme 2), which is easily
accessible in high enantiomeric purity by Sharpless epoxidation of
either penta-1,4-dien-3-ol or penta-2,4-dien-1-ol [53,54]. Pre-
liminary glycosidase inhibition studies indicated that DAJNAc is the
strongest competitive inhibitor of human placenta b-GlcNAcase (b-
hexosaminidase) among the epimeric series, beating the D-gluco
and the D-galacto stereoisomers 2 and 3 [55]. Using this newnd the related acetamido-iminosugars (2e5).
Fig. 1. Optimized structures calculated at DFT level.
A. de la Fuente et al. / European Journal of Medicinal Chemistry 121 (2016) 926e938928scaffold to generate molecular diversity by conjugation was
therefore very appealing. Motivated by the success of sp2-imino-
sugars analogues of the classical iminosugars as modulators of
several lysosomal glycosidases [56e59], we envisioned to selec-
tively modify the endocyclic amine group of 5 into a pseudoamide
functionality bearing different appendages. However, the rather
modest overall yield (16%) of the initial synthesis prevented the
preparation of large amounts of DAJNAc for structural modiﬁcation
and further biological activity studies. Here we report a new
methodology to obtain DAJNAc in 7 steps with 41% overall yield.
This optimization afforded key intermediates that allowed us to get
thiourea and 2-iminothiazolidine sp2-iminosugar conjugates in
high yields. Evaluation of their inhibitory abilities showed signiﬁ-
cant selectivity increases towards human b-hexosaminidase
(placenta), with potencies that in the best cases overpassed that of
the parent DAJNAc. The new compounds have been also evaluated
as potential pharmacological chaperones in ﬁbroblasts harnessing
the G269S mutation in the a-subunit of heterodimeric b-hexosa-
minidase A, the most common disease allele in adult Tay-Sachs
patients [60].
2. Results and discussion
2.1. Synthesis
In our previous synthesis, DAJNAc 5 was obtained after hydro-
lysis of the bicyclic carbamate 6 (40% yield), which in turn was
prepared by dihydroxylation of the key intermediate 10 using N-
methylmorpholine-N-oxide (NMO) and catalytic amounts of
K2OsO4$2H2O in acetone/water (Scheme 2). In accordance with the
widely studied directing effect of allylic amides [61e63], we had
anticipated that the dihydroxylation reaction would proceed pref-
erentially from the same face of the acetamido substituent (a-face).
However, the dihydroxylation of 10 into 6 took place with modest
diastereoselectivity (4:1 ratio allo:galacto) and yield (66%, Scheme
1), thus representing a bottleneck for scaling-up purposes. We
conceived that increasing the steric hindrance at the opposite b-
face of the six-membered ring, by opening the planar oxazolidi-
none ring and introducing appropriate substituents at the primary
oxygen and the nitrogen atom, would further improve the stereo-
selectivity of the reaction in favor of the desired allo derivative.
Indeed, preliminary calculations suggested that the carbonyl oxy-
gen of an acyclic carbamate group at the endocyclic nitrogen (as in
12b) would be suitably disposed to form an intramolecular seven-
membered hydrogen bond with the acetamide proton, thus favor-
ing the 1SN skew-boat conformation over the sofa conformation,
present in the bicyclic carbamate 10 (Fig. 1). Consequently, the
primary carbon C6, vicinal to the double bond, would be shifted
from a pseudoequatorial to a pseudoaxial orientation, thereby
increasing the steric shield on the b-face of the molecule. Such an
increase may, in turn, improve the diastereoselectivity of the
dihydroxylation reaction. In order to conﬁrm this hypothesis, we
explored an alternative synthetic route involving dihydroxylation
of monocyclic enamides 12, which were obtained from 10 after
hydrolysis of the cyclic carbamate functionality (Scheme 2).
The known intermediate 7 was easily prepared in multi-gram
scale from penta-2,4-dien-1-ol [53,54]. Bicyclic acetamide 10 was
obtained as a single diastereomer in 3 steps following the previ-
ously described methodology [55]. After careful optimization of the
reaction conditions, the 2-oxazolidinone ring was hydrolyzed with
NaOH 6 M at reﬂux, and the resulting free amine was protected as
the corresponding tert-butylcarbamate to afford the N-Boc-pro-
tected derivative 11 (80% overall yield). The primary hydroxyl was
next either silylated by treatment with TBSCl/imidazole or acety-
lated with Ac2O/pyridine to give 12a or 12b in 75% and 86% yield,respectively (Scheme 3).
The results for the dihydroxylation of the new N-Boc-protected
enamides using a variety of conditions are shown in Table 1. The
silyl ether derivative 12a showed remarkable selectivity toward the
desired syn diastereomer even under non-asymmetric conditions,
although with moderate yields (Table 1, entries 1 and 2). Sharpless
asymmetric dihydroxylation (AD) conditions using dihy-
droquinidine (DHQD) or dihydroquinine (DHQ) derivatives based
on phthalazine (Phal) or pyrimidine (Pyr) afforded similar results
even when working with the miss-matched chiral ligand (Table 1,
entries 3 and 4). The fourth generation Sharpless ligands based on
anthraquinone (AQN) [64] were also explored, showing a slightly
lower allo/galacto ratio for themiss-matched case (Table 1, entries 5
and 6). These ﬁndings suggested that the observed stereoselectivity
was due to the interplay of the directing effect of the acetamide and
the steric hindrance of the substituent at C6. Excellent diaster-
eoselectivities were obtained in the more favorable conditions.
However, the reaction times, yields, and stability of TBS-
compounds were not considered convenient for high-scale prepa-
rations. Of note, dihydroxylation of the more stable acetate 12b
using K2OsO4$2H2O/NMO gave an excellent yield and diastereo-
isomeric ratio in amuch shorter reaction time. Sharpless conditions
improved the diastereomeric ratio but at the expense of a dramatic
decrease in yield (entries 7e8). Finally, dihydroxylation of com-
pound 11, bearing a free hydroxymethyl substituent, with
K2OsO4$2H2O/NMO evidenced a signiﬁcant decrease in the dia-
stereoselectivity as compared with TBS or the acetylated counter-
parts 12a and 12b (entry 9). The yield was hindered in this case by
difﬁculties in isolating the highly polar triol 13c.
The allo stereochemistry of the major diastereomer 13b was
conﬁrmed by NMR. As a diagnostic tool,1D-NOESYanalysis showed
positive NOE contacts between H2eH3 and H3eH4 Furthermore,
coupling constants between protons H2 and H3 suggest an
equatorial-axial coupling, thus corroborating the allo conﬁguration
and the syn orientation of the dihydroxylation reaction (Fig. 2).
Consistent with our conformational analysis-based prediction,
comparison of the stereochemical outcome of the dihydroxylation
reaction for compounds 11, 12a and 12b illustrated the inﬂuence of
the bulkiness of the C6 substituent on the outcome of the reaction.
However, the role of the acetamide functionality as a stereo-
directing group remained to be checked. According to the work of
Donohoe et al. [65,66], enamides coordinate to the OsO4-alkene
Scheme 3. Synthesis of diols 13aec.
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diastereomer. N-Alkylation of the acetamido group should lead to a
loss of its coordination ability and therefore a drop in reactivity and
stereoselectivity. In order to conﬁrm this point, enamide 10 was
benzylated with BnBr/NaH, the oxazolidone ring was subsequently
opened (NaOH 6 M/reﬂux), and the free amino group generated
was transformed into the corresponding N-Boc-protectedTable 1
Dihydroxylation of 11, 12a and 12b.
Substrate Conditionsa t/day d.r.b Product Yield/%
1 12a OsO4/NMO 2.5 >30: 1c 13a 65
2 12a K2OsO4$2H2O/NMO 2.5 26: 1 13a 74
3 12a AD with (DHQD)2Phal 4 >30: 1c 13a 56
4 12a AD with (DHQ)2Pyr 2 25: 1 13a 79
5 12a AD with (DHQD)2AQN 2 >30: 1c 13a 46
6 12a AD with (DHQ)2AQN 2 8: 1 13a 48
7 12b K2OsO4$2H2O/NMO 1 11: 1 13b 97
8 12b AD with (DHQD)2Phal 1 17: 1 13b 51
9 11 K2OsO4$2H2O/NMO 1 7: 1 13c 48
a AD: Sharpless Asymmetric Dihydroxylation.
b Diastereomeric ratio determined by 1H NMR.
c Only one diastereomer was observed by 1H NMR.derivative 14 (46% yield overall). Acetylation of the primary alcohol
with Ac2O/pyr afforded acetate 15 (84% yield), a structural analog of
12a but with the coordination capacity of the amide diminished.
Dihydroxylation of 15 using K2OsO4$2H2O/NMO with 10%, 30% and
up to equimolar catalyst loadings did not afford the desired prod-
uct, thereby demonstrating the key role of the acetamido group in
both progress of the reaction and diastereoselectivity (Scheme 4).
Finally, N-Boc acetamide 13bwas de-O-acetylated by treatment
with NH3/MeOH, and the carbamate group was hydrolyzed with
HCl/MeOH to give the target acetamido-iminosugar glycomimetic
DAJNAc 5 as the corresponding hydrochloride salt in 91% yield
(Scheme 5). The overall yield of the complete sequence (seven
steps) from carbamate 7 was 41%.Fig. 2. NOESY analysis of 13b.
Scheme 4. Checking the effect of the acetamide group in the dihydroxylation.
Scheme 5. Final deprotection steps to provide DAJNAc$HCl.
Scheme 6. Synthesis of N-thioureido derivatives of DAJNAc.
Scheme 7. Synthesis of 2-iminothiazolidine derivatives of DAJNAc.
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synthesis of DAJNAc conjugates by derivatization of the endocyclic
amine. N-alkylation has been extensively explored in the case of
DNJNAc and DGJNAc 2 and 3, but although signiﬁcant increases in
the inhibition potency against b-GlcNAcase have been achieved for
some derivatives, the approachwas generally inefﬁcient to improve
the selectivity among enzyme isoforms [50]. Interestingly, non-
iminosugar glycomimetics incorporating ﬁve-membered hetero-
cycles containing sulfur and nitrogen (thiazoline, thiadiazol)
[67e69] have shown much higher enzyme discrimination capa-
bilities. In order to access DAJNAc derivatives with this structural
motif, condensation of the six-membered ring of 5 with a 2-
iminothiazolidine fragment was considered. On the one hand,
such transformation modiﬁes the hybridation character of the N-
atom from sp3 to sp2, imposing a distortion of the chair confor-
mation that bettermimics the transition state of enzymatic glycosyl
hydrolysis. On the second hand, the new exocyclic nitrogen is well-
suited to bear substituents that can provide further interactions
with the enzyme.
The synthesis of bicyclic DAJNAc-thiazolidine conjugates started
by the protection of the secondary hydroxyls in 13b by treatment
with Ac2O/pyridine to give 17 in 91% yield. Deprotection of the N-
Boc was carried out with TFA and the resulting secondary amine
was treated in situ with n-butyl, n-octyl, phenyl or benzyl isothio-
cyanate to give thioureas 18aed in good yields. Deprotection of the
acetyl groups in the adducts using sat. NH3/MeOH gave the fully
unprotected N-thioureido derivatives 19a-d in excellent yields
except for 19c, which could not be obtained. In this particular case
the reaction crude showed many products. Among them we could
identify the oxazolidine-2-thione resulting from the attack of the
primary alcohol to the thiourea. The better leaving group capability
of the aniline versus alkylamines would explain the different
behavior of 18c (Scheme 6). On the other hand, treatment of the N0-
butyl and N0-octyl derivatives 18a and 18b with 1:1 MeOH/H2O at
70 C generated the corresponding 2-iminothiazolidines 20a and20b in good yields. Intramolecular attack of the thiocarbonyl sulfur
at the C6 position with concomitant transesteriﬁcation of the sec-
ondary acetates accounts for this transformation. The N0-phenyl
and N0-benzyl thioureas 18c and 18d required heating at reﬂux 1:1
MeOH/H2O to afford the corresponding bicyclic 2-
iminothiazolidines derivatives 20c and 20d in moderate yields
(Scheme 7).2.2. Glycosidase inhibitory activity
Evaluation of the glycosidase inhibitory activity of 5 conﬁrmed
the total selectivity towards hexosaminidases among a panel that
included b-glucosidases (almonds and bovine liver), a-glucosidase
(yeast), a-mannosidase (jack bean), b-mannosidase (Helix pomatia),
trehalase (pig kidney), amyloglucosidase (Aspergillus niger), a-
rhamnosidase (naringinasa; Penicillium decumbens), a-galactosi-
dase (green coffee), b-galactosidase (Escherichia coli), or isomaltase
(yeast). In addition to low mM inhibition of b-N-acetylglucosami-
nidases from different sources (human placenta, Ki 5.6 mM; bovine
kidney, Ki 2.6 mM; jack bean, Ki 2.6 mM), DAJNAc was also found to
inhibit the b-N-acetylgalactosaminidase activity of the enzyme
from jack bean at its optimal pH [70] (Ki 46 mM).
The structure information of b-N-acetylglucosaminidase
[51,69,71] reveals that the vicinity of the enzyme active site con-
tains multiple negative charges. This feature has guided the design
of inhibitors towards compounds containing protonable groups in
the structure and is the main reason why N-alkylation strategies,
keeping the sp3-hybridized character of the endocyclic nitrogen,
have been privileged by other authors in the case of DNJNAc and
DGJNAc conjugates [48]. Yet, interactions of lipophilic moieties
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mental both for glycomimetic conjugates and non-carbohydrate
based inhibitors discovered by high throughput screening. We
thus decided to include thioureas 19a, 19b and 19d in our study.
Whereas a strong decrease in the inhibition potency was observed
for the N0-butyl and N0-octyl conjugates, the N0-benzylthiourea
adduct was almost as potent as the parent iminosugar 5 (Ki 8.6 mM;
Table 2). Most interestingly, the selectivity between the human and
plant enzyme shifted from 1:2.2 to 1.6:1. To the best of our
knowledge, this is the ﬁrst neutral inhibitor of b-GlcNAcase re-
ported up to date, expanding the current portfolio of potential drug
candidates.
The basic character is restored in the bicyclic 2-
iminothiazolidine sp2-iminosugar conjugates, translating into a
dramatic increase in the inhibitory potency, between two and three
orders of magnitude, for the N0-alkyl derivatives 20a and 20b (Ki
values 4.9 and 0.6 mM against the human placenta enzyme,
respectively; Table 2) as compared with the thiourea progenitors
19a and 19b. The inhibition potency enhancement was less signif-
icant for the N0-benzyl analogue 20d (Ki 4.9 mM), whereas the ar-
omatic iminothiazolidine 20c was about 5-fold a weaker inhibitor.
Remarkably, except for 20c, all the new bicyclic sp2-iminosugar
conjugates behaved as more potent inhibitors of human b-GlcNA-
case than the parent monocyclic iminosugar DAJNAc 5, up to almost
10-fold in the case of 20b. Moreover, contrary to 5, they also
exhibited a marked selectivity towards the human enzyme relative
to the plant enzyme.
Unexpectedly, the inhibition trend of the new DNJNAc thioureas
and iminothiazolidines towards total b-hexosaminidase (A and B
isoforms) and b-hexosaminidase A, the isoform dysfuntional in Tay-
Sachs patients, in wild type ﬁbroblast lysates was totally different
from that encountered in the placenta enzyme. Thus, only the N0-
octyl and N0-phenyliminothiazolidines 20b and 20c exhibited
submillimolar IC50 values in the two assays (315 mM against total
hexosaminase, 100 mM against hexosaminisadase A for both com-
pounds). The N0-octylthiourea derivative 19b additionally behaved
as a modest inhibitor of hexosaminisadase A (IC50 350 mM). To the
best of our knowledge, such a sharp difference in the inhibitory
activity towards lysosomal b-hexosaminidases from different tis-
sues has never been reported before. A plausible explanation is that
the DAJNAc derivatives prepared in this work are highly sensitive to
structural differences between the mature and precursor form of
the enzyme. Thus, b-hexosaminidase from human placenta is a
mature form of the lysosomal enzyme, whereas the precursor form
has been reported to be present in the extracellular medium in
which cultured ﬁbroblasts were grown [72].Table 2
Inhibition constants (Ki, mM) against commercial b-N-acetylglucosaminidases for DAJNA
double reciprocal analysisa.
Enzyme origin
5 19a, R ¼ Bu 19b, R ¼ n-Oct 19
Human placenta 5.6 ± 0.3 118 ± 5 909 ± 5 8
Bovine kidney 2.6 ± 0.2 88 ± 3 n.i.b 5
Jack bean 2.6 ± 0.2 75 ± 2 363 ± 5 13
a No signiﬁcant inhibition was detected against b-glucosidases (almonds and bovin
pomatia), trehalase (pig kidney), amyloglucosidase (Aspergillus niger), a-rhamnosidase (
(E. coli), or isomaltase (yeast).
b No inhibition detected a 2 mM concentration.Lysosomal hexosaminidase hydrolyze terminal N-acetyl-b-D-
glucosamine and N-acetyl-b-D-galactosamine residues. Conse-
quently, the contacts of the mismatching allo-conﬁgured DAJNAc
glycomimetics with amino acids at the catalytic site will likely be
poor, the stability of the complex with the enzyme relying much on
aglycone interactions. The peripheral enzyme regions involved in
such aglycone interactions are expected to be more sensitive to
structural differences between the mature and precursor forms of
the enzyme as compared to the catalytic site, which provides a
rational for the observed discrepancies in the inhibitory activities
when going from the placenta enzyme to ﬁbroblast lysates.
The mature b-hexosaminidase from human placenta has been
previously used in high throughput screenings to identify in-
hibitors that could act as pharmacological chaperones against
disease-associated hexosaminidase mutants [42]. However, an
ideal chaperone candidate should bind to the precursor form of the
mutant enzyme (hexosaminidase A in the case of Tay-Sachs dis-
ease) at the endoplasmic reticulum, restore trafﬁcking and disso-
ciate from the mature hexosaminidase at the lysosome. In our case,
the 2-iminothiazolidines 20b and 20c inhibited hexosaminidase A
in ﬁbroblasts (precursor form) with IC50 of 100 mM but were much
stronger ligands of the mature placenta enzyme (IC50 0.6 and
27 mM, respectively), which will likely translate into an unfavorable
chaperone-inhibitor balance. Accordingly, a very modest hexosa-
minidase activity enhancement was observed for 20c (1.2-fold at
2 mM concentration) in ﬁbroblasts heterozygous for the p.G269S/
c.1278insTACT mutations from a Tay-Sachs patient with the adult-
onset form of the disease, whereas 20b was inactive in the
0.2e20 mM concentration range. Interestingly, the thiourea deriv-
ative 19b induced a 30% hexosaminidase activity enhancement at
only 0.2 mM concentration in the same cell line, in spite of its much
weaker ﬁbroblast hexosaminidase A afﬁnity (350 mM). The
ensemble of data strongly suggest that the ratio between the
inhibitory potencies against the placenta and ﬁbroblast hexosa-
minidase provides a much accurate indication for the selection of
pharmacological chaperone candidates for Tay-Sachs disease than
the classical screening using only the placenta enzyme. Using in-
hibition of the mature form of the enzyme as a selection tool bear
the risk to privilege strong inhibitors over good chaperones and
might be at the origin of some disappointing results in clinical trials
[73]. Even though the hexosaminidase activity enhancement ach-
ieved in vitro with the best compound identiﬁed in this work, 19b,
is far from other examples reported in the literature [41,74,75], the
fact that it binds much weakly to the mature as compared to the
precursor enzyme is unprecedented and open the door to optimi-
zation strategies.c (5), 19aed and 20aed determined from thee slope of LineweavereBurk plots and
d, R ¼ Bn 20a, R ¼ Bu 20b, R ¼ n-Oct 20c, R ¼ Ph 20d, R ¼ Bn
.6 ± 0.3 4.9 ± 0.3 0.60 ± 0.05 27 ± 1 4.9 ± 0.4
.9 ± 0.2 2.9 ± 0.2 0.65 ± 0.05 38 ± 2 11 ± 0.5
.4 ± 0.5 24 ± 1 2.3 ± 0.1 20 ± 1 9.5 ± 0.5
e liver), a-glucosidase (yeast), a-mannosidase (jack bean), b-mannosidase (Helix
naringinasa; Penicillium decumbens), a-galactosidase (green coffee), b-galactosidase
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In summary, we have devised a new synthetic route for DAJNAc
5 that increases the yield from 16 to 41% and the diaster-
eoselectivity of the key dihydroxylation step from 4:1 to 11:1 as
compared with the previously reported preparation. This achieve-
ment paves the way for the preparation of large amounts of 5,
currently the best inhibitor of placenta human b-GlcNAcase among
the acetamido-iminosugar analogues of the natural mono-
saccharide 1. Moreover, the orthogonally protected intermediate
13b has been used for the implementation of molecular diversity-
oriented schemes leading to sp2-iminosugar conjugates with a
monocyclic glycone moiety, namely the thiourea derivatives 19a,
19b and 19d, or with a bicyclic skeleton, namely the 2-
iminothiazolidines 20aed. Evaluation of the inhibitory properties
of the new compounds against hexosaminidase from human
placenta and cultured ﬁbroblasts unveiled remarkable disparities
that could be ascribed to differences in the efﬁciency of aglycone
interactions with the mature and precursor forms of the enzyme,
which has been demonstrated to be critical for the identiﬁcation of
pharmacological chaperone candidates for Tay-Sachs disease. It is
worth mentioning that b-hexosaminidase is also the dominant
glycosaminoglycan-degrading glycosidase released by chon-
drocytes into the extracellular milieu [76]. Inhibition of the mature
form of this enzyme can indeed prevent or even reverse cartilage
matrix degradation, representing a newavenue in the development
of therapeutic treatments for osteoarthritis [38,76,77]. Altogether,
the results support that modiﬁcations of the DAJNAc core is a
promising strategy for the development of therapeutic agents
against b-GlcNAcase-related diseases.
4. Experimental
4.1. Theoretical calculations
The structures were fully optimized using DFT at the level
RB3LYP/6-31G** as implemented in Spartan'10 package of pro-
grams [79].
4.2. Chemistry
4.2.1. General remarks
Non-aqueous reactions were carried out under nitrogen atmo-
sphere. Dry dichloromethane was obtained using a Solvent Puriﬁ-
cation System (SPS). Other commercially available reagents and
solvents were used with no further puriﬁcation. All reactions were
monitored by TLC analysis using Merck 60 F254 silica gel on
aluminum sheets. Silica gel chromatography was performed by
using 35e70 mm silica or an automated chromatography system
(Combiﬂash®, Teledyne Isco) with hexanes/ethyl acetate gradients
as eluent unless noted otherwise.
NMR spectra were recorded at room temperature on a Varian
Mercury 400. 1H and 13C NMR spectra were referenced to the re-
sidual peaks of the deuterated solvent. The following abbreviations
were used to deﬁne the multiplicities: s, singlet; d, doublet; t,
triplet; q, quadruplet; m, multiplet; br s, broad signal. The chemical
shifts (d) are expressed in ppm and the coupling constants (J) in
hertz (Hz).
IR spectra were recorded in a Thermo Nicolet Nexus FT-IR
apparatus, either by preparing a KBr disk or by depositing a ﬁlm
of the product on a NaCl plate. Absorptions are given in wave-
numbers (cm1).
Melting points were recorded in a Büchi M-540 apparatus
without recrystallization of the ﬁnal solids.
Optical rotations were measured at room temperature (25 C)using a Jasco P-2000 iRM-800 polarimeter (589 nm). Concentration
(g/100 mL) and solvent are shown in brackets.
High Resolution Mass Spectra were recorded in a LTQ-FT Ultra
(Thermo Scientiﬁc) using the Nanoelectrospray technique.
Elemental analyses were done in an EA-1108 CE Instrument
(Thermo Fisher).
Compounds 8, 9 and 10 were obtained following the previously
described methodology [55].
4.2.2. (2S,5R)-tert-Butyl-5-acetamido-2-(hydroxymethyl)-5,6-
dihydropyridine-1(2H)-carboxylate (11)
NaOH 6 M (2.72 mL, 16.3 mmol) was added to a solution of 10
(320 mg, 1.63 mmol) in acetone:water 10:1 (25 mL), and the
mixture was heated at reﬂux for 7 h. After cooling to rt, the crude
product was neutralized by adding HCl(c) until pH 8, and solvents
were removed in vacuo to give a white solid, which was redissolved
in EtOAc:aqueous saturated NaHCO3 3:1 (20 mL). Boc2O (791 mg,
3.58 mmol) was added, and the mixture was heated at reﬂux for
16 h. The mixture was extracted with EtOAc (3  15 mL), washed
with water (1x 20 mL), dried over MgSO4, and puriﬁed in silica gel
using CH2Cl2/methanol, increasing the polarity ratio from 0 to 15%
MeOH to give 11 (361 mg, 80%) as a white solid.
[a]20D ¼ 115.5 (c ¼ 0.22, CHCl3). Mp: 65e68 C. 1H NMR
(400MHz, CDCl3, d/ppm): 6.08e5.87 (m, 2H), 5.68 (br, 1H), 4.66 (br,
1H), 4.33 (m, 1H), 4.22 (d, J ¼ 14.0 Hz, 1H), 3.70 (m, 2H), 3.13 (dd,
J ¼ 14.0, 2.5 Hz, 1H), 1.96 (s, 3H), 1.47 (s, 9H). 13C NMR (100 MHz,
CDCl3, d/ppm): 169.5 (CO), 156.3 (CO), 129.7 (CH), 126.4 (CH), 80.6
(C), 63.5 (CH2), 53.9 (CH), 43.2 (CH) 43.2 (CH2), 28.4 (CH3), 23.1
(CH3). IR (ﬁlm, nmax/cm1): 3288, 2968, 2917, 1675, 1653, 1422,
1366, 1173, 1133. HRMS (ES): Calcd. for C13H22N2O4: 271.16523,
found 271.16505. EA: Calcd. for C13H22N2O4$2/3 H2O: C, 55.30%; H,
8.33%; N, 9.92%; found C, 55.25%; H, 8.01%; N, 10.07%.
4.2.3. tert-Butyl-(3R,6S)-3-acetamido-6-(((tert-butyldimethylsilyl)
oxy) methyl)-3,6-dihydropyridine-1(2H)-carboxylate (12a)
Compound 11 (70 mg, 0.26 mmol), TBSCl (61 mg, 0.39 mmol),
and imidazole (35 mg, 0.52 mmol) were placed in a 25-mL round
bottom ﬂask and dissolved in CH2Cl2 (5 mL). The reaction was then
stirred at rt for 2 h. Solvents were removed in vacuo, and the crude
product was puriﬁed in SiO2$TEA (2.5% v/v) using hexane/ethyl
acetate 30:70 to obtain 12a (75 mg, 75%) as a colorless oil.
[a]20D ¼ 150.3 (c ¼ 0.11, CHCl3). 1H NMR (400 MHz, CDCl3, d/
ppm): 5.95 (m, 2H), 4.52 (br, 1H), 4.27 (m, 1H), 4.18 (d, J ¼ 13.5 Hz,
1H), 3.68 (m, 2H), 3.18 (m, 1H), 1.94 (s, 3H), 1.44 (s, 9H), 0.86 (s, 9H),
0.02 (s, 6H). 13C NMR (100 MHz, CDCl3, d/ppm): 169.3 (CO), 155.4
(CO), 154.9* (CO), 131.4 (CH), 129.6* (CH), 126.0 (CH), 125.4* (CH),
80.1 (C), 79.7* (C), 63.6 (CH2), 53.9 (CH), 52.9* (CH), 44.1 (CH2), 43.3
(CH), 28.4 (CH3), 25.8 (CH3), 23.1 (CH3), 18.1 (C), 5.6 (CH3)
(*Rotamer signal). IR (ﬁlm, nmax/cm1): 2962, 2929, 1693, 1656,
1421, 1365, 1133, 1104. HRMS (ES): Calcd. for C19H36N2O4Si:
385.25171, found 385.25145.
4.2.4. tert-Butyl-(3R,6S)-3-acetamido-6-(acetoxymethyl)-3,6-
dihydropyridine-1(2H)-carboxylate (12b)
Pyridine (0.45 mL, 5.34 mmol) and acetic anhydride (0.61 mL,
5.77 mmol) were added to a solution of 11 (578 mg, 2.14 mmol) in
32 mL of CH2Cl2. The solution was then stirred at rt for 3 h. Water
(10 mL) was added, and the crude product extracted with CH2Cl2
(3  15 mL), dried over MgSO4, and puriﬁed in silica gel using
CH2Cl2/methanol, increasing the polarity ratio from 0 to 10% MeOH
to give 12b (572 mg, 86%) as a white solid.
[a]20D ¼ 171.1 (c ¼ 0.35, CHCl3). Mp: 142e143 C. 1H NMR
(400 MHz, CDCl3, d/ppm): 6.16e5.66 (m, 3H), 4.83 (br, 1H), 4.64*
(br, 1H), 4.39 (m,1H), 4.22 (d, J¼ 13.5 Hz, 1H), 4.14 (m, 2H), 3.11 (dd,
J ¼ 13.5, 3.0 Hz, 1H), 2.06 (s, 3H), 2.04* (s, 3H), 1.96 (s, 3H), 1.46 (s,
A. de la Fuente et al. / European Journal of Medicinal Chemistry 121 (2016) 926e938 9339H) (*Rotamer signals). 13C NMR (100 MHz, CDCl3, d/ppm): 170.6
(CO), 169.3 (CO), 154.8 (CO), 129.2 (CH), 127.6 (CH), 126.8* (CH), 80.5
(C), 80.1* (C), 63.3 (CH2), 63.1* (CH2), 51.2 (CH), 50.2* (CH), 43.1
(CH), 42.1 (CH2), 28.3 (CH3), 23.0 (CH3), 20.7 (CH3) (*Rotamer
signal). IR (ﬁlm, nmax/cm1): 2968, 1751, 1693, 1661, 1418, 1367,
1239, 1136. HRMS (ES): Calcd. for C15H25N2O5: 313.17580, found
313.17587. EA: Anal. Calcd. for C15H24N2O: C, 57.68%; H, 7.74%; N,
8.97%; found C, 57.77%; H, 7.82%; N, 8.81%.
4.2.5. tert-Butyl-(2R,3R,4S,5S)-5-acetamido-2-(((tert-
butyldimethylsilyl)oxy)methyl)-3,4-dihydroxypiperidine-1-
carboxylate (13a)
N-Methylmorpholine-N-oxide (43 mg, 0.36 mmol) and
K2OsO4$2H2O (6.3 mg,12%) were added to a solution of 12a (55 mg,
0.14 mmol) in acetone:water 10:1 (4 mL). The solution was then
stirred for 2.5 d at rt. Na2S2O3 (40 mg) and MgSO4 were added, and
the reaction was stirred for 1 h and ﬁltered over Celite. Solvents
were remove in vacuo, and the crude product was puriﬁed in silica
gel using CH2Cl2/methanol, increasing the polarity ratio from 0 to
10% MeOH to give 13a (44 mg, 74%) as a colorless oil with a 26:1
diastereoisomer ratio.
1H NMR (400 MHz, CDCl3, d/ppm): 6.92 (br, 1H), 4.42 (t,
J ¼ 6.0 Hz, 1H), 4.24 (dd, J ¼ 6.0, 3.5 Hz 1H), 4.16 (d, J ¼ 14.0 Hz, 1H),
4.10 (s, 1H), 3.97 (t, J ¼ 3.5 Hz, 1H), 3.72 (m, 2H), 3.13 (dd, J ¼ 14.0,
2.5 Hz, 1H), 1.98 (s, 3H), 1.45 (s, 9H), 0.87 (s, 9H), 0.04 (d, J ¼ 1.7 Hz,
6H). 13C NMR (100 MHz, CDCl3, d/ppm): 171.4 (CO), 156.2 (CO), 80.4
(C), 69.7 (CH), 67.1 (CH), 62.4 (CH2), 58.2 (CH), 48.8 (CH), 44.1 (CH2),
28.3 (CH3), 25.8 (CH3), 23.5 (CH3), 18.1 (C),5.6 (CH3). IR (ﬁlm, nmax/
cm1): 3373, 2929, 1693, 1653, 1420, 1155, 1103. HRMS (ES): Calcd.
for C19H39N2O6Si: 419.25719, found 419.25686.
4.2.6. tert-Butyl-(2R,3R,4S,5S)-5-acetamido-2-(acetoxymethyl)-
3,4-dihydroxypiperidine-1-carboxylate (13b)
4.2.6.1. Method A: non-asymmetric conditions.
N-Methylmorpholine N-oxide (751 mg, 6.21 mmol) and
K2OsO4$2H2O (110 mg, 10%) were added to a solution of 12b
(925 mg, 2.96 mmol) in acetone:water 10:1 (27 mL). The solution
was then stirred for 1 d at rt. Na2S2O3 (500 mg) and MgSO4 were
added, and the reaction was stirred for 1 h and ﬁltered over Celite.
Solvents were remove in vacuo, and the crude product was puriﬁed
in silica gel using CH2Cl2/methanol, increasing the polarity ratio
from 0 to 15% MeOH to give 13b (1.01 g, 97%) as a white solid with a
11:1 diastereoisomer ratio.
4.2.6.2. Method B: sharpless asymmetric dihydroxylation.
(DHQD)2Phal (6.1 mg, 5%), K2OsO4$2H2O (1.4 mg, 2.5%), K3[Fe(CN)6]
(153mg, 0.46mmol) and K2CO3 (64 mg, 0.46 mmol) were dissolved
in water (1.5 mL) and cooled at 0 C. Methanesulfonamide (15 mg,
0.15 mmol) was added in one portion. After 5 min, a solution of 12b
(48 mg, 0.15 mmol) in tBu-OH (1.5 mL) was added. The mixturewas
vigorously stirred at 0 C for 20min, then allowed towarm to rt and
stirred for 1 d. Na2S2O3 (150mg) was added. After 30min, the crude
product was extracted with EtOAc (3  5 mL), dried over MgSO4,
and puriﬁed in silica gel using CH2Cl2/methanol, increasing the
polarity ratio from 0 to 15% MeOH to give 13b (27 mg, 51%) as a
white solid with a 17:1 diastereoisomer ratio.
[a]20D ¼ þ13.5 (c ¼ 0.25, CHCl3). Mp: 47e49 C. 1H NMR
(400 MHz, CDCl3, d/ppm): 7.02 (br, 1H), 4.75 (t, J ¼ 6.5 Hz, 1H), 4.27
(m, 1H), 4.20 (d, J ¼ 14.5 Hz, 1H), 4.17 (s, 1H), 4.15 (d, J¼ 2.5 Hz, 1H),
3.99 (s, 1H), 3.82 (dd, J ¼ 4.5, 3.0 Hz, 1H), 3.04 (dd, J ¼ 14.5, 2.5 Hz,
1H), 2.06 (s, 3H), 1.99 (s, 3H), 1.46 (s, 9H). 13C NMR (100 MHz, CDCl3,
d/ppm): 171.4 (CO), 170.6 (CO), 156.1 (CO), 80.7 (C), 68.9 (CH), 66.6
(CH), 60.7 (CH2), 55.8 (CH), 48.8 (CH), 42.9 (CH2), 28.3 (CH3), 23.4
(CH3), 20.8 (CH3). IR (ﬁlm, nmax/cm1): 3377, 2968, 1741, 1689, 1431,
1366, 1254, 1146. HRMS (ES): Calcd. for C15H27N2O7: 347.18128,found 347.18134. EA: Calcd. for C15H26N2O7$H2O: C, 49.44%; H,
7.75%; N, 7.69%; found C, 49.75%; H, 7.71%; N, 7.74%.
4.2.7. tert-Butyl (2R,3R,4S,5S)-5-acetamido-3,4-dihydroxy-2-
(hydroxymethyl)piperidine-1-carboxylate (13c)
N-Methylmorpholine-N-oxide (47 mg, 0.39 mmol) and
K2OsO4$2H2O (8.2 mg, 12%) were added to a solution of 11 (50 mg,
0.18 mmol) in acetone:water 10:1 (5 mL). The solution was then
stirred for 1 d at rt. Na2S2O3 (45 mg) and MgSO4 were added, and
the reaction was stirred for 1 h and ﬁltered over Celite. Solvents
were removed in vacuo, and the crude product was puriﬁed in silica
gel using CH2Cl2/methanol, increasing the polarity ratio from 0 to
20% MeOH to give 13c (27 mg, 48%) as a white solid and one
diastereoisomer.
[a]20D¼þ28.6 (c¼ 0.31, CH3OH). 1H NMR (400MHz, CD3OD, d/
ppm): 7.74 (d, J ¼ 7.5 Hz, 1H), 4.45 (tt, J ¼ 7.5, 2.0 Hz, 1H), 4.24 (ddd,
J ¼ 14.0, 3.0, 2.0 Hz, 1H), 4.02 (m, 2H), 3.84 (dd, J ¼ 4.5, 3.0 Hz, 1H),
3.63 (m, 2H), 3.01 (dd, J ¼ 14.0, 2.0 Hz, 1H), 1.96 (s, 3H), 1.45 (s, 9H).
13C NMR (100 MHz, CD3OD, d/ppm): 173.0 (CO), 158.0 (CO), 81.2 (C),
70.3 (CH), 66.6 (CH), 60.5 (CH, CH2), 51.4 (CH), 43.9 (CH2), 28.6
(CH3), 23.3 (CH3).
IR (ﬁlm, nmax/cm1): 3367, 2975, 1658, 1425, 1366, 1147. HRMS
(ES): Calcd. for C13H25N2O6: 305.17071, found 305.17062.
4.2.8. tert-Butyl (3R,6S)-3-(N-benzylacetamido)-6-
(hydroxymethyl)-3,6-dihydropyridine-1(2H)-carboxylate (14)
BnBr (108 mL, 0.89 mmol) was added to a suspension of NaH
(18 mg, 0.71 mmol), tBuONa (3.4 mg, 0.03 mmol) and 10 (70 mg,
0.35mmol) in 3mL of DMF, and themixturewas stirred for 4 h at rt.
After water (3 mL) addition, the crude product was extracted with
CH2Cl2 (3x 5 mL), and solvents were removed in vacuo. The yellow
oil was redissolved in MeOH:H2O 9:1 (8 mL), then NaOH 6 M
(0.85 mL, 5.09 mmol), was added and the mixture was stirred 16 h
at reﬂux. After allowing the mixture to cool to rt, HCl(c) was added
until a pH of 7e8 was achieved. Solvents were removed in vacuo,
and the white solid obtained was redissolved in EtOAc:aq NaHCO3
sat (12 mL). Boc2O (247 mg, 1.12 mmol) was added, and the mixture
was stirred at reﬂux for 4 h. The crude product was extracted with
EtOAc (3x 5 mL), dried over MgSO4, and puriﬁed in silica gel using
hexane/ethyl acetate, increasing the polarity ratio from 0 to 100%
ethyl acetate to give 14 (65 mg, 48%) as a colorless oil.
[a]20D ¼169.7 (c ¼ 0.18, CH3OH). 1H NMR (400 MHz, CDCl3, d/
ppm): 7.32 (t, J ¼ 7.5 Hz, 2H), 7.24 (t, J ¼ 7.5 Hz, 1H), 7.10 (d,
J ¼ 7.5 Hz, 2H), 5.91 (dd, J ¼ 10.5, 4.0 Hz, 1H), 5.79 (br, 1H), 5.09 (br,
1H), 4.64 (br, 1H), 4.53 (d, J ¼ 17.5 Hz, 1H), 4.46 (d, J ¼ 17.5 Hz, 1H),
4.31 (d, J ¼ 14.5 Hz, 1H), 3.68 (m, 2H), 3.23 (dd, J ¼ 14.5, 4.0 Hz, 1H),
2.00 (s, 3H), 1.47 (s, 9H). 13C NMR (100 MHz, CDCl3, d/ppm): 171.9
(CO), 138.4 (C), 131.0 (CH), 128.8 (CH), 127.1 (CH), 125.6 (CH), 125.4
(CH), 80.6 (C), 63.6 (CH2), 54.0 (CH), 48.9 (CH2), 47.8 (CH), 43.6
(CH2), 28.4 (CH3), 22.4 (CH3). IR (ﬁlm, nmax/cm1): 3404, 1691, 1648,
1450, 1365, 1170, 1027. HRMS (ES): Calcd. for C20H29N2O4: 361.2122,
found 361.2122.
4.2.9. tert-Butyl (3R,6S)-6-(acetoxymethyl)-3-(N-
benzylacetamido)-3,6-dihydropyridine-1(2H)-carboxylate (15)
Pyridine (37 mL, 0.44 mmol) and Ac2O (40 mL, 0.38 mmol) were
added to a solution of 14 (63 mg, 0.17 mmol) and DMAP (8 mg,
0.07 mmol) in CH2Cl2 (4 mL). The solution was allowed to stir
overnight. Then water (2 mL) was added, and the crude product
was extracted with CH2Cl2 (3  5 mL), dried over MgSO4, and pu-
riﬁed in silica gel using hexane/ethyl acetate, increasing the po-
larity ratio from 0 to 100% ethyl acetate to give 15 (51 mg, 72%) as a
colorless oil.
[a]20D ¼ 177.6 (c ¼ 0.2, CHCl3). 1H NMR (400 MHz, CDCl3, d/
ppm): 7.31 (t, J ¼ 7.5 Hz, 2H), 7.24 (t, J ¼ 7.5 Hz, 1H), 7.09 (d,
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J ¼ 18.0 Hz, 1H), 4.43 (d, J ¼ 18.0 Hz, 1H), 4.30 (m, 1H), 4.13 (s, 2H),
3.22 (dd, J ¼ 14.5, 4.0 Hz, 1H), 2.04 (s, 3H), 2.00 (s, 3H), 1.47 (s, 9H).
13C NMR (100 MHz, CDCl3, d/ppm): 172.0 (CO), 170.7 (CO), 154.5
(CO), 138.4 (C), 130.8 (CH), 129.8* (CH), 128.7 (CH), 127.1 (CH), 126.3
(CH), 126.0* (CH), 125.4 (CH), 80.1 (C), 63.3 (CH2), 51.0 (CH), 50.3*
(CH), 49.0 (CH2), 48.5* (CH2), 47.8 (CH), 46.6* (CH), 43.7 (CH2), 42.8*
(CH2), 28.4 (CH3), 22.4 (CH3), 20.8 (CH3). (* Rotamer signals). IR
(ﬁlm, nmax/cm1): 2975, 1744, 1694, 1649, 1417, 1365, 1237, 1171.
HRMS (ES): Calcd. for C22H31N2O5: 403.2227, found 403.2228.
4.2.10. N-((3S,4S,5R,6R)-4,5-Dihydroxy-6-(hydroxymethyl)
piperidin-3-yl)acetamide hydrochloride (DAJNAc·HCl, 5)
Compound 13b (39 mg, 0.11 mmol) was dissolved in a saturated
methanol solution of NH3 (2 mL) and stirred for 2 h. Solvent was
removed in vacuo, and the crude product was redissolved in HCl
1.25 M MeOH solution (2.5 mL) and stirred for 3 h. Solvent was
removed in vacuo, and the crude product was puriﬁed in silica gel
using CH2Cl2/methanol/NH3, increasing polarity ratio from 99:0:1
to 85:13:2 to give 5 (21 mg, 91%) as a white solid.
[a]20D ¼ þ3.0 (c ¼ 0.13, CH3OH). Mp: 45e48 C. 1H NMR
(400 MHz, CD3OD, d/ppm): 4.21 (dt, J ¼ 9.0, 2.0 Hz, 1H), 4.00 (t,
J ¼ 2.0 Hz, 1H), 3.91 (dd, J ¼ 12.0, 3.0 Hz, 1H), 3.85 (dd, J ¼ 12.0,
5.0 Hz, 1H), 3.75 (dd, J ¼ 10.5, 3.0 Hz, 1H), 3.29 (m, J ¼ 5.0 Hz, 1H),
3.13 (s, 1H), 3.11 (s, 1H), 2.02 (s, 3H). 13C NMR (100 MHz, CD3OD, d/
ppm): 173.4 (CO), 69.7 (CH), 67.4 (CH), 59.0 (CH2), 56.7 (CH), 47.8
(CH), 41.5 (CH2), 22.4 (CH3). IR (ﬁlm, nmax/cm1): 3308, 2936, 1652,
1546, 1533, 1367, 1079, 1034. HRMS (ES): Calcd. For C8H17N2O4:
205.11828, found 205.11832.
4.2.11. (2R,3R,4S,5S)-5-Acetamido-2-(acetoxymethyl)-1-(tert-
butoxycarbonyl)piperidine-3,4-diyl diacetate (17)
To a solution of compound 13b (380 mg, 1.1 mmol) in CH2Cl2
(13 mL) was added pyridine (0.27 mL, 3.3 mmol) and acetic anhy-
dride (0.28 mL, 2.4 mmol) dropwise. The solution was allowed to
stir for 16 h. Solvents were removed in vacuo and the crude was
puriﬁed by chromatography on silica gel using CH2Cl2/methanol
increasing polarity ratio from 0 to 10% to give 17 (432 mg, 91%) as a
white sticky foam.
[a]20D ¼ þ14.1 (c ¼ 0.35, CHCl3).1H NMR (400 MHz, CDCl3, d/
ppm): 6.33 (br, 1H), 5.25 (m, 1H), 5.14 (dd, J ¼ 4.5, 3.5 Hz, 1H), 4.75
(br, 1H), 4.39 (s, 1H), 4.31 (m, 2H), 4.18 (dd, J¼ 11.5, 6.0 Hz, 1H), 3.15
(dd, J ¼ 14.5, 2.0 Hz, 1H), 2.16 (s, 3H), 2.09 (s, 3H), 2.04 (s, 3H), 2.02
(s, 3H), 1.46 (s, 9H). 13C NMR (100 MHz, CDCl3, d/ppm): 170.2 (CO),
169.5 (CO), 169.4 (CO), 168.7 (CO), 155.3 (CO), 80.9 (C), 68.9 (CH),
66.0 (CH), 60.6 (CH2), 53.9 (CH), 46.2 (CH), 43.2 (CH2), 28.2 (CH3),
23.4 (CH3), 20.9 (CH3), 20.6 (CH3), 20.6 (CH3). IR (ﬁlm, nmax/cm1):
2975, 1747, 1691, 1412, 1368, 1228, 1152, 1059. HRMS (ES): Calcd. for
C19H31N2O9: 431.20241, found 431.20283.
4.2.12. (2R,3R,4S,5S)-5-Acetamido-2-(acetoxymethyl)-1-
(butylcarbamothioyl)piperidine-3,4-diyl diacetate (18a)
To a solution of 17 (63 mg, 0.15 mmol) in CH2Cl2 (3 mL) was
added TFA (0.35 mL) and the solution was stirred at rt for 1 h.
Solvent was removed in vacuo. The crude was dissolved in CH2Cl2
(4 mL) and TEA (164 mL, 1.17 mmol) and butyl isothiocyanate (54 mL,
0.44 mmol) were added. The solution was stirred at reﬂux for 4 h.
After removal of solvents, the crude was puriﬁed in silica gel using
hexane/ethyl acetate increasing polarity ratio from 0 to 100% ethyl
acetate to give 18a (47 mg, 73%) as a colorless oil.
[a]20D ¼ 74.6 (c ¼ 0.25, CHCl3). 1H NMR (400 MHz, CDCl3, d/
ppm): 6.65 (d, J ¼ 7.5 Hz, 1H), 6.39 (d, J ¼ 4.5 Hz, 1H), 5.35 (br, 1H),
5.25 (m, 2H), 4.89 (d, J ¼ 15.0 Hz, 1H), 4.43 (dd, J ¼ 11.5, 7.0 Hz, 2H),
4.19 (dd, J ¼ 11.5, 7.0 Hz, 1H), 3.64 (m, 2H), 3.30 (dd, J ¼ 15.0, 3.0 Hz,
1H), 2.14 (s, 3H), 2.12 (s, 3H), 2.06 (s, 3H), 2.00 (s, 3H), 1.61 (m, 2H),1.39 (m, 2H), 0.96 (t, J ¼ 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3, d/
ppm): 185.4 (CS), 170.9 (CO), 170.3 (CO), 169.6 (CO), 169.2 (CO), 68.8
(CH), 66.4 (CH), 61.4 (CH2), 57.7 (CH), 47.0 (CH), 46.5 (CH2), 45.5
(CH2), 30.9 (CH2), 23.4 (CH3), 20.9 (CH3), 20.7 (CH3), 20.6 (CH3), 20.0
(CH2), 13.7 (CH3). IR (ﬁlm, nmax/cm1): 3327, 2957, 1747, 1666, 1530,
1369, 1222, 1058. HRMS (ES): calcd. for C19H31N3O7S: 446.19555,
found 446.19593.
4.2.13. (2R,3R,4S,5S)-5-Acetamido-2-(acetoxymethyl)-1-
(octylcarbamothioyl)piperidine-3,4-diyl diacetate (18b)
To a solution of 17 (110 mg, 0.26 mmol) in CH2Cl2 (4 mL) was
added TFA (0.61 mL) and the solution was stirred at rt for 2 h.
Solvent was removed in vacuo. The crude was dissolved in CH2Cl2
(5 mL) and TEA (213 mL, 1.53 mmol) and octyl isothiocyanate
(128 mL, 0.64 mmol) were added. The solution was stirred at reﬂux
for 4 h. After removal of solvents, the crudewas puriﬁed in silica gel
using hexane/ethyl acetate increasing polarity ratio from 0 to 100%
ethyl acetate to give 18b (90 mg, 70%) as a colorless oil.
[a]20D ¼ 66.4 (c ¼ 0.11, CHCl3). 1H NMR (400 MHz, CDCl3, d/
ppm): 6.64 (d, J¼ 7.5 Hz,1H), 6.36 (s,1H), 5.34 (br,1H), 5.25 (m, 2H),
4.89 (d, J ¼ 15.0 Hz, 1H), 4.43 (dd, J ¼ 12.0, 7.0 Hz, 2H), 4.19 (dd,
J¼ 12.0, 7.0 Hz, 1H), 3.62 (m, 2H), 3.29 (dd, J¼ 15.0, 3.0 Hz,1H), 2.13
(s, 3H), 2.12 (s, 3H), 2.06 (s, 3H), 1.99 (s, 3H), 1.61 (m, 2H), 1.30 (m,
10H), 0.88 (t, J ¼ 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3, d/ppm):
185.4 (CS), 170.9 (CO), 170.3 (CO), 169.6 (CO), 169.2 (CO), 68.8 (CH),
66.4 (CH), 61.4 (CH2), 57.8 (CH), 47.0 (CH), 46.9 (CH2), 45.5 (CH2),
31.7 (CH2), 29.2 (CH2), 29.1 (CH2), 28.9 (CH2), 26.9 (CH2), 23.4 (CH3),
22.6 (CH2), 20.9 (CH3), 20.7 (CH3), 20.6 (CH3), 14.0 (CH3). IR (ﬁlm,
nmax/cm1): 3359, 2917, 1747, 1661, 1529, 1368, 1229, 1053. HRMS
(ES): Calcd. for C23H39N3O7S: 502.2581, found 502.2586.
4.2.14. (2R,3R,4S,5S)-5-Acetamido-2-(acetoxymethyl)-1-
(phenylcarbamothioyl)piperidine-3,4-diyl diacetate (18c)
To a solution of 17 (120 mg, 0.28 mmol) in CH2Cl2 (5 mL) was
added TFA (0.65 mL) and the solution was stirred at rt for 2 h.
Solvent was removed in vacuo. The crude was dissolved in CH2Cl2
(5 mL) and TEA (186 mL, 1.36 mmol) and phenyl isothiocyanate
(103 mL, 0.83 mmol) were added. The solution was stirred at reﬂux
for 4 h. After removal of solvents, the crudewas puriﬁed in silica gel
using hexane/ethyl acetate increasing polarity ratio from 0 to 100%
ethyl acetate to give 18c (92 mg, 72%) as a colorless oil.
[a]20D ¼ 41.4 (c ¼ 0.6, CHCl3). 1H NMR (400 MHz, CDCl3, d/
ppm): 8.26 (s, 1H), 7.40e7.28 (m, 4H), 7.20 (dt, J ¼ 7.5, 1.5 Hz, 1H),
6.76 (d, J¼ 7.0 Hz, 1H), 5.62 (br, 1H), 5.29 (m, 2H), 4.90 (m, 1H), 4.45
(m, 2H), 4.29 (dd, J¼ 12.0, 6.0 Hz, 1H), 3.37 (dd, J¼ 15.0, 3.0 Hz, 1H),
2.15 (s, 3H), 2.14 (s, 3H), 2.07 (s, 3H),1.99 (s, 3H). 13C NMR (100MHz,
CDCl3, d/ppm): 185.9 (CS), 170.6 (CO), 170.3 (CO), 169.5 (CO), 169.1
(CO), 139.6 (C), 128.8 (CH), 125.8 (CH), 124.6 (CH), 69.0 (CH), 66.2
(CH), 61.5 (CH2), 58.3 (CH), 47.3 (CH), 46.3 (CH2), 23.4 (CH3), 20.9
(CH3), 20.7 (CH3), 20.6 (CH3). IR (ﬁlm, nmax/cm1): 3346, 1747, 1665,
1523, 1369, 1230, 1060. HRMS (ES): Calcd. for C21H28N3O7S:
466.1642, found 466.1648.
4.2.15. (2R,3R,4S,5S)-5-Acetamido-2-(acetoxymethyl)-1-
(benzylcarbamothioyl)piperidine-3,4-diyl diacetate (18d)
To a solution of 17 (96 mg, 0.22 mmol) in CH2Cl2 (5 mL) was
added TFA (0.5 mL) and the solutionwas stirred at rt for 1 h. Solvent
was removed in vacuo. The crude was dissolved in CH2Cl2 (5 mL)
and TEA (186 mL, 1.36 mmol) and benzyl isothiocyanate (90 mL,
0.67 mmol) were added. The solution was stirred at reﬂux for 5 h.
After removal of solvents, the crude was puriﬁed in silica gel using
hexane/ethyl acetate increasing polarity ratio from 0 to 100% ethyl
acetate to give 18d (88 mg, 82%) as a colorless oil.
[a]20D ¼ 61.8 (c ¼ 0.25, CHCl3). 1H NMR (400 MHz, CDCl3, d/
ppm): 7.39e7.28 (m, 5H), 6.63 (m, 2H), 5.46 (br, 1H), 5.24 (m, 2H),
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2H), 4.19 (dd, J¼ 12.0, 6.0 Hz,1H), 3.33 (dd, J¼ 15.0, 3.0 Hz,1H), 2.13
(s, 3H), 2.05 (s, 3H), 1.98 (s, 3H), 1.89 (s, 3H). 13C NMR (100 MHz,
CDCl3, d/ppm): 185.8 (CS), 170.6 (CO), 170.3 (CO), 169.5 (CO), 169.2
(CO), 137.6 (C), 128.7 (CH), 127.9 (CH), 127.8 (CH), 68.9 (CH), 66.4
(CH), 61.4 (CH2), 58.3 (CH), 50.4 (CH2), 47.1 (CH), 45.5 (CH2), 23.3
(CH3), 20.9 (CH3), 20.6 (CH3), 20.6 (CH3). IR (ﬁlm, nmax/cm1): 3308,
1748, 1668, 1532, 1370, 1226, 1059, 1027. HRMS (ES): Calcd. for
C22H29N3O7SNa: 502.1618, found 502.1621.
4.2.16. N-((3S,4S,5R,6R)-1-(Butylcarbamothioyl)-4,5-dihydroxy-6-
(hydroxymethyl)piperidin-3-yl)acetamide (19a)
Compound 18a (47 mg, 0.11 mmol) was dissolved in a saturated
solution of NH3 in MeOH (3.5 mL) and stirred at rt for 20 h. Solvent
was removed in vacuo. The crude was puriﬁed by chromatography
in silica gel using CH2Cl2/methanol increasing polarity ratio from
0 to 15% MeOH to give 19a (26 mg, 77%) as a white solid.
[a]20D ¼ þ2.0 (c ¼ 0.21, CH3OH). Mp: 57e58 C. 1H NMR
(400 MHz, CD3OD, d/ppm): 5.03 (d, J ¼ 14.0 Hz, 1H), 4.13 (m, 1H),
3.99 (dt, J ¼ 3.0, 1.0 Hz, 1H), 3.88 (dd, J ¼ 5.0, 3.0 Hz, 1H), 3.74 (m,
2H), 3.64 (m,1H), 3.55 (m,1H), 3.20 (dd, J¼ 14.0, 3.0 Hz,1H), 1.96 (s,
3H), 1.58 (m, 2H), 1.38 (m, 2H), 0.95 (t, J ¼ 7.0 Hz, 3H). 13C NMR
(100 MHz, CD3OD, d/ppm): 186.8 (CS), 173.5 (CO), 70.6 (CH), 67.2
(CH), 65.3 (CH), 60.7 (CH2), 51.3 (CH), 47.5 (CH2), 46.9 (CH2), 32.3
(CH2), 23.3 (CH3), 21.1 (CH2), 14.2 (CH3). IR (ﬁlm, nmax/cm1): 3341,
2923, 1652, 1538, 1360, 1328, 1085, 1008. HRMS (ES): calcd. For
C13H25N3O4S: 320.1639, found 320.1640. EA: Anal. Calcd. For
C13H25N3O4S$H2O: C, 46.27%; H, 8.07%; N, 12.45%; found C, 46.47%;
H, 8.25%; N, 12.12%.
4.2.17. N-((3S,4S,5R,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-1-
(octylcarbamothioyl)piperidin-3-yl)acetamide (19b)
Compound 18b (72 mg, 0.14 mmol) was dissolved in a saturated
solution of NH3 in MeOH (4 mL) and stirred at rt for 20 h. Solvent
was removed in vacuo. The crude was puriﬁed by chromatography
in silica gel using CH2Cl2/methanol increasing polarity ratio from
0 to 20% MeOH to give 19b (46 mg, 85%) as a white solid.
[a]20D ¼ þ3.3 (c ¼ 0.25, CH3OH). Mp: 84e86 C. 1H NMR
(400 MHz, CD3OD, d/ppm): 5.03 (d, J ¼ 14.5 Hz, 1H), 4.15 (m, 1H),
3.99 (td, J ¼ 3.0, 1.0 Hz, 1H), 3.88 (dd, J ¼ 4.5, 3.0 Hz, 1H), 3.74 (m,
2H), 3.62 (m, 1H), 3.52 (m, 1H), 3.20 (dd, J ¼ 14.5, 2.5 Hz, 1H), 1.60
(m, 2H), 1.33 (m, 10H), 0.90 (t, J ¼ 7.0 Hz, 3H). 13C NMR (100 MHz,
CD3OD, d/ppm): 186.7 (CS), 173.4 (CO), 70.6 (CH), 67.2 (CH), 65.3
(CH), 60.7 (CH2), 51.3 (CH), 47.5 (CH2), 47.2 (CH2), 33.0 (CH2), 30.5
(CH2), 30.4 (CH2), 30.1 (CH2), 28.0 (CH2), 23.7 (CH2), 23.4 (CH3), 14.4
(CH3). IR (ﬁlm, nmax/cm1): 3346, 2924,1657,1636,1535,1367,1085.
HRMS (ES): Calcd. For C17H33N3O4S: 376.2265, found 376.2264. EA:
Anal. Calcd. For C17H33N3O4S: C, 54.37%; H, 8.86%; N, 11.19%; found
C, 54.05%; H, 8.88%; N, 11.23%.
4.2.18. N-((3S,4S,5R,6R)-1-(Benzylcarbamothioyl)-4,5-dihydroxy-
6-(hydroxymethyl)piperidin-3-yl)acetamide (19d)
Compound 18d (88 mg, 0.18 mmol) was dissolved in a saturated
solution of NH3 in MeOH (3.5 mL) and stirred at rt for 20 h. Solvent
was removed in vacuo to give 19d (92 mg, 92%) as a white solid
without extra puriﬁcation.
[a]20D ¼ þ11.6 (c ¼ 0.22, CH3OH). Mp: 164e165 C. 1H NMR
(400 MHz, CD3OD, d/ppm): 7.42e7.15 (m, 5H), 5.09 (d, J ¼ 14.0 Hz,
1H), 4.93 (d, J ¼ 15.0 Hz, 2H), 4.79 (d, J ¼ 15.0 Hz, 1H), 4.15 (m, 1H),
4.01 (dt, J ¼ 3.0, 2.0 Hz, 1H), 3.90 (dd, J ¼ 5.0, 3.0 Hz, 1H), 3.75 (m,
2H), 3.25 (dd, J ¼ 14.0, 2.0 Hz, 1H), 1.92 (s, 3H). 13C NMR (100 MHz,
CD3OD, d/ppm): 187.3 (CS), 173.5 (CO), 140.3 (C), 129.4 (CH), 128.4
(CH), 128.0 (CH), 70.6 (CH), 67.2 (CH), 65.4 (CH), 60.6 (CH2), 51.4
(CH), 50.5 (CH2), 47.7 (CH2), 23.3 (CH3). IR (ﬁlm, nmax/cm1): 3333,
1661, 1636, 1553, 1531, 1373, 1085, 1002. HRMS (ES): calcd. ForC16H24N3O4S: 354.1482, found 354.1481. EA: Anal. Calcd. For
C16H23N3O4S$2/3H2O: C, 52.59%; H, 6.71%; N, 11.50%; found C,
52.56%; H, 7.06%; N, 11.27%.
4.2.19. N-((6S,7S,8R,8aS,Z)-3-(Butylimino)-7,8-
dihydroxyhexahydro-3H-thiazolo[3,4-a]pyridin-6-yl)acetamide
(20a)
Compound 18a (40 mg, 0.10 mmol) was dissolved in MeOH:H2O
1:1 mixture (4 mL) and stirred at 70 C for 24 h. Solvent was
removed in vacuo. The crude was puriﬁed by chromatography in
silica gel using CH2Cl2/methanol/NH4OH increasing polarity ratio
from 99:1:1 to 80:18:2 to give 20a (16 mg, 59%) as a white solid.
[a]20D ¼ þ16.4 (c ¼ 0.11, CH3OH). Mp: 188e190 C. 1H NMR
(400 MHz, CD3OD, d/ppm): 3.95 (m, 2H), 3.76 (m, 1H), 3.61 (m, 1H),
3.45 (dd, J¼ 10.0, 2.5 Hz, 1H), 3.38 (dd, J¼ 10.5, 6.5 Hz, 1H), 3.15 (m,
2H), 3.06 (dd, J¼ 10.5, 7.5 Hz, 1H), 2.89 (m,1H), 1.98 (s, 3H), 1.52 (m,
2H),1.36 (m, 2H), 0.93 (t, J¼ 7.5 Hz, 3H). 13C NMR (100MHz, CD3OD,
d/ppm): 172.9 (CO), 162.7 (CN), 72.6 (CH), 71.5 (CH), 61.3 (CH), 55.6
(CH2), 49.0 (CH), 43.1 (CH2), 34.3 (CH2), 31.2 (CH2), 22.6 (CH3), 21.5
(CH2), 14.3 (CH3). IR (ﬁlm, nmax/cm1): 3319, 2925, 1621, 1547, 1373,
1056. HRMS (ES): Calcd. for C13H24N3O3S: 302.1533, found
302.1532.
4.2.20. N-((6S,7S,8R,8aS,Z)-3-(Butylimino)-7,8-
dihydroxyhexahydro-3H-thiazolo[3,4-a]pyridin-6-yl)acetamide
(20b)
Compound 18b (54 mg, 0.11 mmol) was dissolved in MeOH:H2O
1:1 mixture (4 mL) and stirred at 70 C for 24 h. Solvent was
removed in vacuo. The crude was puriﬁed by chromatography in
silica gel using CH2Cl2/methanol/NH4OH increasing polarity ratio
from 99:1:1 to 80:18:2 to give 20b (27 mg, 70%) as a white solid.
[a]20D ¼ þ11.5 (c ¼ 0.13, CH3OH). Mp: 180e181 C. 1H NMR
(400 MHz, CD3OD, d/ppm): 3.95 (m, 2H), 3.76 (m, 1H), 3.62 (m, 1H),
3.46 (dd, J ¼ 9.5, 2.5 Hz, 1H), 3.39 (dd, J ¼ 10.5, 6.5 Hz, 1H), 3.15 (m,
2H), 3.07 (dd, J ¼ 11.0, 7.5 Hz, 1H), 2.90 (dd, J ¼ 12.0, 11.0 Hz, 1H),
1.98 (s, 3H), 1.55 (m, 2H), 1.30 (m, 10H), 0.90 (m, 3H). 13C NMR
(100 MHz, CD3OD, d/ppm): 172.9 (CO), 162.9 (CN), 72.6 (CH), 71.5
(CH), 61.4 (CH), 55.7 (CH2), 49.0 (CH), 43.1 (CH2), 33.0 (CH2), 32.0
(CH2), 31.2 (CH2), 30.5 (CH2), 30.4 (CH2), 28.3 (CH2), 23.7 (CH2), 22.6
(CH3), 14.5 (CH3). IR (ﬁlm, nmax/cm1): 3315, 2923, 1621, 1546, 1443,
1303, 1226, 1057. HRMS (ES): calcd. For C17H32N3O3S: 358.2159,
found 358.2158. EA: Anal. Calcd. For C17H31N3O3S$H2O: C, 54.37%;
H, 8.86%; N, 11.19%; found C, 54.76%; H, 9.23%; N, 8.18%.
4.2.21. N-((6S,7S,8R,8aS,Z)-7,8-Dihydroxy-3-(phenylimino)
hexahydro-3H-thiazolo[3,4-a]pyridin-6-yl)acetamide (20c)
Compound 18c (59 mg, 0.13 mmol) was dissolved in MeOH:H2O
1:1 mixture (5 mL) and stirred at reﬂux for 24 h. Solvent was
removed in vacuo. The crude was puriﬁed by chromatography in
silica gel using CH2Cl2/methanol/NH4OH increasing polarity ratio
from 99:1:1 to 80:18:2 to give 20c (22 mg, 54%) as a white solid.
[a]20D ¼ 11.7 (c ¼ 0.16, CH3OH). Mp: 229e231 C. 1H NMR
(400 MHz, CD3OD, d/ppm): 7.24 (m, 2H), 7.03 (m, 1H), 6.88 (m, 2H),
4.05 (m, 2H), 3.96 (dd, J ¼ 12.0, 5.0 Hz, 1H), 3.77 (m, 1H), 3.53 (dd,
J¼ 10.0, 2.5 Hz,1H), 3.36 (dd, J¼ 10.0, 6.5 Hz,1H), 3.05 (m, 2H), 2.00
(s, 3H). 13C NMR (100 MHz, CD3OD, d/ppm): 172.9 (CO), 163.0 (CN),
152.8 (C), 129.8 (CH), 124.5 (CH), 123.3 (CH), 72.7 (CH), 71.5 (CH),
61.4 (CH), 49.0 (CH), 43.0 (CH2), 31.3 (CH2), 22.6 (CH3). IR (ﬁlm,
nmax/cm1): 3304, 1616, 1586, 1375, 1250, 1137, 762. HRMS (ES):
Calcd. For C15H20N3O3S: 322.12199, found 322.12175.
4.2.22. N-((6S,7S,8R,8aS,Z)-3-(Benzylimino)-7,8-
dihydroxyhexahydro-3H-thiazolo[3,4-a]pyridin-6-yl)acetamide
(20d)
Compound 18d (56 mg, 0.12 mmol) was dissolved in MeOH:H2O
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removed in vacuo. The crude was puriﬁed by chromatography in
silica gel using CH2Cl2/methanol/NH4OH increasing polarity ratio
from 99:1:1 to 90:9:1 to give 20d (26 mg, 66%) as a white solid.
[a]20D ¼ þ6.8 (c ¼ 0.2, CH3OH). Mp: 190e192 C. 1H NMR
(400 MHz, CD3OD, d/ppm): 7.28 (m, 4H), 7.20 (m, 1H), 4.41 (d,
J ¼ 15.0 Hz, 1H), 4.36 (d, J ¼ 15.0 Hz, 1H), 3.99 (m, 2H), 3.87 (m, 1H),
3.72 (m, 1H), 3.49 (dd, J ¼ 9.5, 2.5 Hz, 1H), 3.44 (dd, J ¼ 11.0, 6.5 Hz,
1H), 3.14 (dd, J¼ 11.0, 7.5 Hz, 1H), 2.98 (m,1H), 1.97 (s, 3H). 13C NMR
(100 MHz, CD3OD, d/ppm): 172.9 (CO), 164.4 (CN), 141.3 (C), 129.3
(CH), 128.5 (CH), 127.8 (CH), 72.5 (CH), 71.5 (CH), 61.7 (CH), 58.7
(CH2), 49.0 (CH), 43.1 (CH2), 31.4 (CH2), 22.6 (CH3). IR (ﬁlm, nmax/
cm1): 3327, 1612, 1540, 1450, 1380, 1213, 1046, 752. HRMS (ES):
Calcd. For C16H22N3O3S: 336.13764, found 336.13739. EA: Anal.
Calcd. For C16H21N3O3S: C, 57.29%; H, 6.31%; N, 12.53%; found C,
57.73%; H, 6.38%; N, 12.21%.
4.3. General procedures for inhibition and chaperone assays
4.3.1. Kinetic studies with commercial glycosidases
The glycosidases a-glucosidase (from yeast), amyloglucosidase
(from A. niger), isomaltase (from yeast), b-glucosidases (from
almond and bovine liver), naringinase (Penicillium decumbes), a-
galactosidase (from green coffee beans), b-galactosidase (from E.
coli), a-mannosidase (from jack bean), b-mannosidase (from H.
pomatia), b-N-acetylglucosaminidases (from human placenta,
bovine kidney and jack bean) used in the inhibition studies, as well
as the corresponding o- or p-nitrophenyl glycoside substrates, were
purchased from Sigma Chemical Co. Inhibitory potencies were
determined by spectrophotometrically measuring the residual hy-
drolytic activities of the glycosidases against the respective o- (for
b-galactosidases) or p-nitrophenyl a- or b-D-glycopyranoside (for a-
glucosidases, b-glucosidases, a-galactosidases, a-mannosidases
and b-mannosidases) or p-nitrophenyl-N-acetyl-b-D-glucosami-
nide/galactosaminide (for hexosaminidases), in the presence of
DAJNAc. Each assay was performed in phosphate-citrate (for a or b-
mannosidase, amyloglucosidase or b-N-acetylglucosaminidase at
pH 5.5 or 3.5) or in phosphate buffer (at pH 7.3 or 6.8 for the other
glycosidases) at the optimal pH for each enzyme. The Km values for
the different glycosidases used in the tests and the corresponding
working pHs are listed herein: a-glucosidase (yeast), Km¼ 0.35mM
(pH 6.8); amyloglucosidase (A. niger), Km ¼ 3.0 mM (pH 5.5); iso-
maltase (from yeast), Km ¼ 1.0 mM (pH 6.8); b-glucosidase
(almond), Km ¼ 3.5 mM (pH 7.3); b-glucosidase (bovine liver),
Km ¼ 1.0 mM (pH 7.3); naringinase (P. decumbes), Km ¼ 2.7 mM (pH
6.8); a-galactosidase (coffee beans), Km ¼ 2.0 mM (pH 6.8); b-
galactosidase (from E. coli), Km ¼ 0.12 mM (pH 7.3); a-mannosidase
(jack bean), Km ¼ 2.0 mM (pH 5.5); b-mannosidase (H. pomatia),
Km ¼ 0.6 mM (pH 5.5); b-N-acetylglucosaminidase (from human
placenta), Km ¼ 0.34 mM (pH 5.5); b-N-acetylglucosaminidase
(from bovine kidney), Km ¼ 0.48 mM (pH 5.5); b-N-acetylglucosa-
minidase (from jack bean), Km ¼ 0.49 mM (pH 5.5). The latter
enzyme was also assayed for its b-N-acetylgalactosaminidase ac-
tivity; Km ¼ 0.31 mM (pH 3.5). The reactions were initiated by
addition of enzyme to a solution of the substrate in the absence or
presence of various concentrations of inhibitor. After the mixture
was incubated for 10e30 min at 37 C (or 55 C for amyloglucosi-
dase), the reaction was quenched by addition of 1 M Na2CO3. The
absorbance of the resulting mixture was determined at 405 nm.
The Ki value and enzyme inhibition mode were determined from
the slope of LineweavereBurk plots and double reciprocal analysis
using a Microsoft Ofﬁce Excel 2007 program. Inhibition mode of
DAJNAc was competitive against human placenta b-N-acetylglu-
cosaminidase and non-competitive against bovine kidney and jack
bean b-N-acetylglucosaminidase.4.3.2. Hexosaminidase assay and measurement of inhibition
activities in vitro
The ﬂuorogenic 4-methyumbellyferone-conjugated substrates,
4-MU-(2-acetamido-2-deoxy)-b-D-glucopyranoside for total hex-
osaminidase and 4-MU-N-acetyl-b-D-glucosaminide-6-sulfate so-
dium salt for hexosaminidase A, were purchased from Sigma Japan
(Tokyo, Japan) and Slater& Frith Ltd (Norwich, UK) respectively. For
measurement of enzyme activities, cell lysates in 0.1% Triton X-100
in distilled water were mixed with 4-MU substrate solution and
was incubated at 37 C. The reaction terminated with 0.2 M glycin-
NaOH (pH 10.7) and the librated 4-MU was measured with a
ﬂuorescence plate reader (ex. 340 nm and em. 460 nm; Inﬁnite
F500, TECAN Japan, Kawasaki, Japan). For measurement of inhibi-
tion activities, cell lysates from cultured human normal skin ﬁ-
broblasts were mixed with 4-MU substrates and compounds and
incubate at 37 C. The activities were measured as described above.
4.3.3. Cell culture and chaperone treatment
Human skin ﬁbroblasts from unaffected subject were cultured
as described [58,78]. Human ﬁbroblasts from Tay-Sachs disease
patient with p.G269S/c.1278insTACT HEXA mutations were ob-
tained from Coriell Cell Repositories (Camden, NJ). For measure-
ment of chaperone effects, cells were cultured in the mediumwith
or without compounds for 4 days and then the cell lysates were
subjected for the lysosomal enzyme assay as described above. The
enzyme activities were normalized with protein concentrations
measured by protein assay rapid kit (Wako, Tokyo, Japan).
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